BR112017013015A2 - método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef) - Google Patents
método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)Info
- Publication number
- BR112017013015A2 BR112017013015A2 BR112017013015A BR112017013015A BR112017013015A2 BR 112017013015 A2 BR112017013015 A2 BR 112017013015A2 BR 112017013015 A BR112017013015 A BR 112017013015A BR 112017013015 A BR112017013015 A BR 112017013015A BR 112017013015 A2 BR112017013015 A2 BR 112017013015A2
- Authority
- BR
- Brazil
- Prior art keywords
- hfpef
- heart failure
- ejection fraction
- treating
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 230000003177 cardiotonic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014905194A AU2014905194A0 (en) | 2014-12-22 | Method of Treatment | |
| PCT/AU2015/050820 WO2016101024A1 (en) | 2014-12-22 | 2015-12-21 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017013015A2 true BR112017013015A2 (pt) | 2018-03-06 |
Family
ID=56148784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017013015A BR112017013015A2 (pt) | 2014-12-22 | 2015-12-21 | método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef) |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10493067B2 (https=) |
| EP (1) | EP3236963B1 (https=) |
| JP (2) | JP2018500365A (https=) |
| KR (1) | KR20170098897A (https=) |
| CN (1) | CN107530337B (https=) |
| AU (1) | AU2015372434B2 (https=) |
| BR (1) | BR112017013015A2 (https=) |
| EA (1) | EA201791455A1 (https=) |
| IL (1) | IL253028B (https=) |
| MX (1) | MX2017008248A (https=) |
| SG (1) | SG11201704980XA (https=) |
| WO (1) | WO2016101024A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018500365A (ja) * | 2014-12-22 | 2018-01-11 | カーディオラ ピーティーワイ リミテッド | 治療方法 |
| EP4259138A4 (en) * | 2020-12-10 | 2024-11-06 | Imbria Pharmaceuticals, Inc. | METHODS OF TREATING CARDIAC DISORDERS USING MODIFIED FORMS OF TRIMETAZIDINE |
| US11969422B2 (en) | 2020-12-10 | 2024-04-30 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine |
| US11730733B2 (en) | 2020-12-10 | 2023-08-22 | Imbria Pharmaceuticals, Inc. | Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine |
| US12076318B2 (en) | 2020-12-10 | 2024-09-03 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine |
| US11793807B2 (en) | 2020-12-10 | 2023-10-24 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4297360A (en) | 1980-03-28 | 1981-10-27 | Sterling Drug Inc. | 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use |
| IL61501A (en) | 1979-11-26 | 1984-06-29 | Sterling Drug Inc | 5-(pyridinyl)-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them |
| US4313951A (en) | 1979-11-26 | 1982-02-02 | Sterling Drug Inc. | 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor |
| GB8414220D0 (en) | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| US5213811A (en) | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
| DK0707475T3 (da) | 1993-06-14 | 1997-12-29 | Janssen Pharmaceutica Nv | Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin |
| US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
| GB9402203D0 (en) | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
| AU2003261298A1 (en) | 2002-08-02 | 2004-02-23 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| KR100548925B1 (ko) | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | 약물의 경구투여용 서방성 조성물 |
| US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| TW200517106A (en) | 2003-10-29 | 2005-06-01 | Wyeth Corp | Sustained release pharmaceutical compositions |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| AU2009346606B2 (en) | 2009-05-20 | 2016-06-02 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
| CN103608662B (zh) * | 2011-06-29 | 2016-09-28 | 京都府公立大学法人 | 肿瘤部位的识别装置以及识别方法 |
| CN104023725B (zh) * | 2011-08-16 | 2019-04-26 | 卡迪欧拉有限公司 | 控释制剂 |
| CN106117194A (zh) | 2011-12-27 | 2016-11-16 | 铁木医药有限公司 | 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类 |
| WO2013116194A2 (en) | 2012-01-30 | 2013-08-08 | O'connell Timothy D | Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis |
| JP2018500365A (ja) * | 2014-12-22 | 2018-01-11 | カーディオラ ピーティーワイ リミテッド | 治療方法 |
-
2015
- 2015-12-21 JP JP2017534610A patent/JP2018500365A/ja not_active Revoked
- 2015-12-21 EA EA201791455A patent/EA201791455A1/ru unknown
- 2015-12-21 US US15/538,123 patent/US10493067B2/en active Active
- 2015-12-21 KR KR1020177020214A patent/KR20170098897A/ko not_active Withdrawn
- 2015-12-21 WO PCT/AU2015/050820 patent/WO2016101024A1/en not_active Ceased
- 2015-12-21 MX MX2017008248A patent/MX2017008248A/es unknown
- 2015-12-21 EP EP15871347.9A patent/EP3236963B1/en active Active
- 2015-12-21 SG SG11201704980XA patent/SG11201704980XA/en unknown
- 2015-12-21 AU AU2015372434A patent/AU2015372434B2/en active Active
- 2015-12-21 CN CN201580076215.4A patent/CN107530337B/zh active Active
- 2015-12-21 BR BR112017013015A patent/BR112017013015A2/pt not_active Application Discontinuation
-
2017
- 2017-06-20 IL IL253028A patent/IL253028B/en active IP Right Grant
-
2019
- 2019-12-02 US US16/700,237 patent/US11291660B2/en active Active
-
2021
- 2021-12-24 JP JP2021210184A patent/JP7475324B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107530337B (zh) | 2021-07-09 |
| IL253028B (en) | 2019-12-31 |
| NZ732954A (en) | 2021-11-26 |
| SG11201704980XA (en) | 2017-07-28 |
| EP3236963A1 (en) | 2017-11-01 |
| US20170348292A1 (en) | 2017-12-07 |
| EA201791455A1 (ru) | 2017-12-29 |
| WO2016101024A1 (en) | 2016-06-30 |
| CN107530337A (zh) | 2018-01-02 |
| KR20170098897A (ko) | 2017-08-30 |
| JP2018500365A (ja) | 2018-01-11 |
| CA2971071A1 (en) | 2016-06-30 |
| MX2017008248A (es) | 2018-02-19 |
| US11291660B2 (en) | 2022-04-05 |
| AU2015372434A1 (en) | 2017-07-13 |
| US20200101053A1 (en) | 2020-04-02 |
| AU2015372434B2 (en) | 2018-10-04 |
| EP3236963B1 (en) | 2020-01-29 |
| US10493067B2 (en) | 2019-12-03 |
| JP7475324B2 (ja) | 2024-04-26 |
| EP3236963A4 (en) | 2018-08-08 |
| JP2022163681A (ja) | 2022-10-26 |
| IL253028A0 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500153A1 (en) | Compositions and methods of use for treating metabolic disorders | |
| EP4620519A3 (en) | Methods and compositions relating to chondrisomes from blood products | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| PH12017500680A1 (en) | Compositions and methods of use for treating metabolic disorders | |
| BR112017013015A2 (pt) | método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef) | |
| IL249061B (en) | Combination, composition, and method of administering the combination or composition to animals | |
| EP3316822A4 (en) | HYBRID HEADLAPS FOR EXPANSION AFTER IMPLANTATION | |
| EP3261713A4 (en) | Blood pump for treatment of bradycardia | |
| PH12016500582B1 (en) | Heterocyclic compounds and uses thereof | |
| WO2014160281A3 (en) | Method of enhancing delivery of therapeutic compounds to the eye | |
| DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
| MX376700B (es) | Compuestos heterociclicos fusionados como moduladores s1p. | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| PH12016501769B1 (en) | Treatment of intrahepatic cholestatic diseases | |
| TN2016000177A1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
| HK1253320A1 (zh) | 用於治疗aml的药物组合物和治疗有此需要的对象中的aml的方法 | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
| EP3256137A4 (en) | Method of treating heart failure | |
| MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
| MX2017004842A (es) | Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica). | |
| MX2016013979A (es) | Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina. | |
| TH1501007280A (th) | สูตรผสมที่ใช้ทางปากสำหรับการบำบัดโรคหัวใจและระบบหมุนเวียนโลหิต (Cardiovascular Diseases) | |
| AU2015905370A0 (en) | System and computer-implemented method of administering co-operative business interactions | |
| AU2014904843A0 (en) | Method and system for people to locate and communicate with each other as part of an exclusive social club. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |